ORIGINAL ARTICLE   

Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 April;177(4):158-64

DOI: 10.23736/S0393-3660.17.03508-2

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Genetic polymorphism of CYP2D6*41 in different ethnicities of Iranian population

Zohre POURKARAMI ^{1, 2}, M. Hosein SANGTARASH ², Narges JAFARZADEH ¹, Zohre POURSINA ³, Azra IZANLOO ¹, Masoud HOUSHMAND ⁴ ✉

¹ Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran; ² Department of Biology, Faculty of Basic Sciences, University of Sistan and Balouchestan, Zahedan, Iran; ³ Department of Biology, Faculty of Basic Sciences, Islamic Azad university East Tehran Branch, Tehran, Iran; ⁴ Department of Medical Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran

BACKGROUND: We investigated the frequency, prevalence and distribution of CYP2D6*41 polymorphism among different ethnicities of Iranian population.
METHODS: Genotyping was performed using PCR-RFLP method on genomic DNA of blood samples from 300 healthy individuals. Then, DNA sequencing technique was applied on some random samples to confirm the results.
RESULTS: Allele frequencies were 64% and 36% for CYP2D6*41[2988G] and CYP2D6*41[2988A]. The most frequency of CYP2D6*41[2988A] allele in ethnicities was owned by Lur ethnicity (42%) and in terms of geographical distribution, the highest prevalence was seen in the southern areas of the country.
CONCLUSIONS: According to this data, lower drug dose should be considered for people who show this polymorphism rather than normal individuals.

KEY WORDS: Pharmacokinetics - Polymorphism, genetic - Cytochrome P-450 enzyme system